Emma Hethershaw

Emma Hethershaw

Auto-generated profile, based on publicly available information

Emma Hethershaw

Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, LS2 9JT Leeds, United Kingdom

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2013 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
EHE. L. Hethershaw
E. L. Hethershaw
ACA. L. Cilia La Corte
A. L. Cilia La Corte
CDCedric Duval
Cedric Duval
MAM. Ali
M. Ali
PGP. J. Grant
P. J. Grant
HPH. Philippou
H. Philippou
Background Factor XIII is a 320 kDa tetramer, comprising two enzymatic A‐subunits and two carrier B‐subunits (FXIII A2B2). Activated FXIII (FXIIIa) catalyses the formation of ε‐(γ‐glutamyl)lysyl covalent bonds between γ‐γ, γ‐α and α‐α chains of adjacent fibrin molecules and also cross‐links the major plasmin inhibitor, α2‐antiplasmin, to fibrin. Objectives We investigated the role of FXIII cross‐linking of fibrin directly in clot morphology and its functional effect on clot formation and lysis, in the absence of α2‐antiplasmin. Results and Conclusions Our data show that the presence of FXIII during clot formation results in fibrin clots that have a significant 2.1‐fold reduction in pore size, as determined by the Darcy constant, Ks, and formed thinner fibers (74.7 ± 1.5 nm) and higher density of fibers compared with those without FXIII (86.0 ± 1.7 nm, P < 0.001), as determined by scanning electron microscopy. Additionally, fibrinolysis showed a significant increase in the time to lysis for clots formed in the presence of FXIII in both static and flow systems. These data demonstrate that independent of α2‐antiplasmin, FXIII activity plays a role in increasing the stability of the fibrin clot by altering its structure and increasing the resistance to fibrinolysis.

5 August 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SSSneha Singh
Sneha Singh
JDJohannes Dodt
Johannes Dodt
PVPeter Volkers
Peter Volkers
EHEmma Hethershaw
Emma Hethershaw
HPHelen Philippou
Helen Philippou
Arijit BiswasArijit Biswas
Arijit Biswas
The dimeric FXIII-A2, a pro-transglutaminase is the catalytic part of the heterotetrameric coagulation FXIII-A2B2 complex that upon activation by calcium binding/thrombin cleavage covalently cross-links preformed fibrin clots protecting them from premature fibrinolysis. Our study characterizes the recently disclosed three calcium binding sites of FXIII-A concerning evolution, mutual crosstalk, thermodynamic activation profile, substrate binding, and interaction with other similarly charged ions. We demonstrate unique structural aspects within FXIII-A calcium binding sites that give rise to functional differences making FXIII unique from other transglutaminases. The first calcium binding site showed an antagonistic relationship towards the other two. The thermodynamic profile of calcium/thrombin-induced FXIII-A activation explains the role of bulk solvent in transitioning its zymogenic dimeric form to an activated monomeric form. We also explain the indirect effect of solvent ion concentration on FXIII-A activation. Our study suggests FXIII-A calcium binding sites could be putative pharmacologically targetable regions.

4 January 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
KKKatherine Jennifer Kearney
Katherine Jennifer Kearney
JBJuliet Butler
Juliet Butler
OPOlga M. Posada
Olga M. Posada
CWClare Wilson
Clare Wilson
SHSamantha Heal
Samantha Heal
HPHelen Philippou
Helen Philippou
Significance: Prekallikrein (PK) is a zymogen that is converted to kallikrein (PKa) by factor (F)XIIa. PK and FXII reciprocally activate each other; the resulting FXIIa initiates activation of the coagulation system via the cleavage of FXI to FXIa, which then activates FIX. This manuscript describes a novel high-affinity binding interaction between FIX(a) and PK(a) and reports that PKa can dose- and time-dependently activate FIX to generate FIXa, resulting in thrombin generation and clot formation independent of FXIa. Characterization of the kinetics of FIX activation reveal that PKa is a more significant activator of FIX than previously considered. This work highlights a new amendment to the coagulation cascade where PKa can directly activate FIX.

1 August 2015 in Thrombosis Research
Verified
Journal Article
Closed access
JKJoke Konings
Joke Konings
LHLisa R. Hoving
Lisa R. Hoving
RARobert A.S. Ariens
Robert A.S. Ariens
EHEmma L. Hethershaw
Emma L. Hethershaw
MNMarisa Ninivaggi
Marisa Ninivaggi
JGJosé W.P. Govers-Riemslag
José W.P. Govers-Riemslag

1 July 2016 in Human Mutation
Verified
Journal Article
Closed access
PDF file
ATAnne Thomas
Anne Thomas
Arijit BiswasArijit Biswas
Arijit Biswas
JDJohannes Dodt
Johannes Dodt
HPHelen Philippou
Helen Philippou
EHEmma Hethershaw
Emma Hethershaw
JOJohannes Oldenburg
Johannes Oldenburg

19 April 2018 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
EHE. L. Hethershaw
E. L. Hethershaw
PAP. J. Adamson
P. J. Adamson
KSK. A. Smith
K. A. Smith
WGW. N. Goldsberry
W. N. Goldsberry
RPR. J. Pease
R. J. Pease
HPH. Philippou
H. Philippou
Essentials The roles of β‐barrels 1 and 2 in factor XIII (FXIII) are currently unknown. FXIII truncations lacking β‐barrel 2, both β‐barrels, or full length FXIII, were made. Removing β‐barrel 2 caused total loss of activity, removing both β‐barrels returned 30% activity. β‐barrel 2 is necessary for exposure of the active site cysteine during activation. Summary Background Factor XIII is composed of an activation peptide segment, a β‐sandwich domain, a catalytic core, and, finally, β‐barrels 1 and 2. FXIII is activated following cleavage of its A‐subunits by thrombin. The resultant transglutaminase activity leads to increased resistance of fibrin clots to fibrinolysis. Objectives To assess the functional roles of β‐barrels 1 and 2 in FXIII, we expressed and characterized the full‐length FXIII A‐subunit (FXIII‐A) and variants truncated to residue 628 (truncated to β‐barrel 1 [TB1]), residue 515 (truncated to catalytic core [TCC]), and residue 184 (truncated to β‐sandwich). Methods Proteins were analyzed by gel electrophoresis, circular dichroism, fluorometric assays, and colorimetric activity assays, clot structure was analyzed by turbidity measurements and confocal microscopy, and clot formation was analyzed with a Chandler loop system. Results and Conclusions Circular dichroism spectroscopy and tryptophan fluorometry indicated that full‐length FXIII‐A and the truncation variants TCC and TB1 retain their secondary and tertiary structure. Removal of β‐barrel 2 (TB1) resulted in total loss of transglutaminase activity, whereas the additional removal of β‐barrel 1 (TCC) restored enzymatic activity to ~ 30% of that of full‐length FXIII‐A. These activity trends were observed with physiological substrates and smaller model substrates. Our data suggest that the β‐barrel 1 domain protects the active site cysteine in the FXIII protransglutaminase, whereas the β‐barrel 2 domain is necessary for exposure of the active site cysteine during activation. This study demonstrates the importance of individual β‐barrel domains in modulating access to the FXIII active site region.